Daily Check-Ins, Delayed Signals: What Smartphone Pain Diaries Actually Deliver to Regulators

For most of the modern clinical trial era, a pain study ran on paper. Participants kept a diary at home, filled it out — more or less faithfully — and brought it back to the research site at their next visit. Site coordinators transcribed scores, queries were issued, and by the time an FDA reviewer saw the data, weeks or months had passed since the moment of measurement.

That world is rapidly disappearing. In recent analgesic programs, including the phase III investigations of nerve growth factor (NGF) inhibitors such as tanezumab, electronic patient-reported outcome (ePRO) tools became the backbone of data collection. Participants logged pain intensity on study-provided apps or devices daily, sometimes multiple times per day, and wearable sensors added activity counts, gait metrics, and sleep data on top. The result is a dataset of a scale pain research has never had before — and a set of questions regulators are still learning to answer.

From Clinic Visits to Continuous Streams

The appeal of digital endpoints is straightforward. Traditional trial assessments capture a patient's pain at a single moment, in an unfamiliar exam room, filtered through recall and the desire to be a "good" participant. A daily app check-in, completed at home in the minutes after waking or before bed, arguably reflects the lived experience of chronic pain more honestly — the 3 a.m. flare, the morning stiffness, the walk to the mailbox that suddenly became possible.

In the tanezumab program, ePRO collection allowed investigators to track pain trajectories with a granularity that clinic visits alone could never provide. Regulators reviewing the program noted that daily diary data helped characterize both the magnitude and the durability of analgesic effect over months rather than snapshots. For a chronic condition like osteoarthritis, where the goal is sustained function rather than a single good day, that distinction matters.

Wearables extend the picture further. Step counts and actigraphy data can corroborate a patient's self-reported improvement with objective movement — a partial check against the optimism bias that plagues subjective endpoints.

The Noise Problem

But volume is not the same as signal. Every additional data point is also an additional opportunity for error, omission, and misinterpretation.

Consider what a daily pain score actually contains. It reflects last night's sleep, the weather, a family argument, a missed dose of an over-the-counter analgesic, and — only sometimes — the study drug. When thousands of participants generate months of daily entries, the noise floor rises accordingly. Sponsors and reviewers must then decide what counts as a clinically meaningful change, and pre-specified thresholds that look reasonable in a protocol can behave differently when applied to a high-frequency stream.

Rare adverse events present a subtler challenge. A participant who develops early signs of a serious joint problem may not attribute the symptom to the drug and may never enter it into an app designed to ask about pain intensity, not joint swelling or mechanical symptoms. The very convenience of a structured digital diary can funnel attention toward the questions the app asks and away from the symptoms it doesn't. Adverse event detection still depends on human inquiry at study visits — and if digital convenience subtly reduces the frequency or depth of those visits, the safety net thins precisely where it matters most.

What Regulators Are Learning to Ask

The FDA has generally welcomed ePRO and sensor data, and its guidance documents on patient-reported outcomes predate the current wearable boom. But the agency's reviewers increasingly probe how these tools were validated, whether the app version of a questionnaire performs equivalently to the paper original, and how missing data — the abandoned app, the dead battery, the participant who stopped checking in after a bad week — were handled.

Missingness deserves particular attention. In pain trials, the patients who drop out of data collection are often the ones doing worst on the drug. A digital diary makes non-response visible in real time, which is an advantage over paper — but only if the analysis plan treats those gaps as informative rather than simply imputing them away.

There is also a privacy dimension that US patients increasingly care about. Activity data and location-stamped diary entries are health information of a granular kind, and trial consent forms have not always kept pace with what wearable data could theoretically reveal.

A Tool, Not a Verdict

The honest assessment is that digital diaries have made analgesic trials more informative and more complicated at the same time. They capture the texture of daily pain that clinic visits miss, and they give safety monitors earlier glimpses of emerging patterns. They also generate volumes of data that require careful, pre-specified handling — and they cannot replace the structured adverse-event inquiry that caught the joint-safety concerns which ultimately defined the NGF inhibitor story.

For patients considering enrollment in a digitally instrumented pain trial, the practical takeaway is simple: ask what the app is collecting, what happens to that data after the study, and — most importantly — who is still going to ask you, in person, how you're really doing.